New products and services available to urologists.
Bladder cancer test gains approval for U.S. market
For more information, visit http://www.ikonisys.com/.
For more information, visit http://www.cookmedical.com/.
Rechargeable headset system never needs new bulbs
Cherry Hill, NJ-The Bright Star LED headset system from Vision USA is powered by rechargeable AA batteries and offers a number of viewing options and features, including an adjustable knob, cushioned head loupe, direct LED light, dual pivot points, and on/off switch. The headset is available alone or with +1.5-, +2.0-, and +2.5-range clip-on magnifiers. Options include a transformer with a 9-foot cord and charger with seven AA batteries. An alternative to the headset is the Bright Star LED clip-on, which attaches to eye and safety glasses with a coated, no-scratch clip.
For more information, visit http://www.visionusa.biz/.
Continence curriculum assists regulatory compliance
Bothell, WA-Verathon Inc. has rolled out a revised, downloadable edition of the Program of Excellence in Extended Care, by Diane K. Newman, RNC, MSN, co-director of the Penn Center for Continence and Pelvic Health, University of Pennsylvania Medical Center. The continuing education program trains extended care facility staffs in assessing and managing residents' urinary health in order to comply with the Centers for Medicare & Medicaid Services' revised FTag 315 regulations. Completion of the program secures 5.0 CE credits from the Society of Urologic Nurses and Associates.
For more information, visit http://www.verathon.com/.
Transducer soaking system has large, contoured funnel
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.